[1] This glucose-dependent mechanism significantly reduces the risk of hypoglycemia when used alone, though this risk increases when combined with insulin or sulfonylureas
It honestly feels like Ive turned the clock back like Im back in my forties, instead of constantly feeling worn out by the job.
What's New: July 2026 Update TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients Eli Lilly's pivotal Phase 3 obesity trial met all primary and key secondary endpoints 45.3% of patients on 12mg lost 30% of body weight surgical-level outcomes confirmed in the largest retatrutide trial to date 104-week extension: patients with BMI 35 reached up to 30.3% average weight loss weight loss did not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First completed Phase 3 trial in type 2 diabetes up to -2.0% HbA1c reduction and 16.8% weight loss in 537 patients, a separate program from TRIUMPH OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a baseline of 58.6 events/hour NDA on track: Industry estimates continue to expect Q4 2026 filing following TRIUMPH-1 and TRIUMPH-4 data TRIUMPH-2 and TRIUMPH-3 results still expected later in 2026 this page updates monthly Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly
Improved Metabolic Health Weight loss and wellness treatments often focus on improving overall metabolic health
The increases peaked around week 24 and then declined
Factors such as current weight, age, health status, activity level, and consistency with treatment and follow-up can all influence your individual weight loss experience
Steeksleutels"" loading="lazy"/>
